Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1991 1
1992 2
1996 1
1997 2
1998 2
1999 2
2001 2
2002 2
2003 3
2004 4
2006 2
2007 4
2009 1
2010 1
2011 1
2012 3
2013 1
2014 1
2015 1
2016 1
2017 3
2018 2
2019 6
2020 5
2021 5
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Kearon C, et al. Among authors: goldhaber sz. Chest. 2012 Feb;141(2 Suppl):e419S-e496S. doi: 10.1378/chest.11-2301. Chest. 2012. PMID: 22315268 Free PMC article.
PEITHO Long-Term Outcomes Study: Data Disrupt Dogma.
Goldhaber SZ. Goldhaber SZ. J Am Coll Cardiol. 2017 Mar 28;69(12):1545-1548. doi: 10.1016/j.jacc.2017.01.027. J Am Coll Cardiol. 2017. PMID: 28335836 Free article. No abstract available.
Fibrinolysis for acute pulmonary embolism.
Piazza G, Goldhaber SZ. Piazza G, et al. Among authors: goldhaber sz. Vasc Med. 2010 Oct;15(5):419-28. doi: 10.1177/1358863X10380304. Vasc Med. 2010. PMID: 20926501 Review.
Patients with massive PE present with syncope, systemic arterial hypotension, cardiogenic shock, or cardiac arrest and have the highest risk for short-term mortality and adverse events. The majority of deaths from acute PE are due to RV pressure overload and subsequent RV …
Patients with massive PE present with syncope, systemic arterial hypotension, cardiogenic shock, or cardiac arrest and have the highest risk …
Risk stratification of acute pulmonary embolism.
Kucher N, Goldhaber SZ. Kucher N, et al. Among authors: goldhaber sz. Semin Thromb Hemost. 2006 Nov;32(8):838-47. doi: 10.1055/s-2006-955466. Semin Thromb Hemost. 2006. PMID: 17171598 Review.
Risk stratification facilitates identification of high-risk patients and may be helpful in guiding the initial and long-term management. In patients with massive PE and hemodynamic instability, rapid risk assessment is paramount and bedside echocardiography and multislice …
Risk stratification facilitates identification of high-risk patients and may be helpful in guiding the initial and long-term manageme …
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Fontana P, Goldhaber SZ, Bounameaux H. Fontana P, et al. Among authors: goldhaber sz. Eur Heart J. 2014 Jul 21;35(28):1836-43. doi: 10.1093/eurheartj/ehu027. Epub 2014 Feb 7. Eur Heart J. 2014. PMID: 24510637 Review.
Direct oral anticoagulants (DOACs) specifically target factor IIa or Xa and represent a major step forward in the treatment of acute- and long-term prevention of venous thrombo-embolism (VTE). They are at least as effective and as safe as conventional therapy (heparins and …
Direct oral anticoagulants (DOACs) specifically target factor IIa or Xa and represent a major step forward in the treatment of acute- and lo …
Prevention of recurrent idiopathic venous thromboembolism.
Goldhaber SZ. Goldhaber SZ. Circulation. 2004 Dec 14;110(24 Suppl 1):IV20-4. doi: 10.1161/01.CIR.0000150641.65000.f2. Circulation. 2004. PMID: 15598644 Review.

Clinical trials show that the benefit associated with extended anticoagulation therapy < or =1 year in patients with idiopathic VTE is not maintained over the long term once treatment is discontinued. Controlled trials have established the efficacy of indefinite-duratio

…

Clinical trials show that the benefit associated with extended anticoagulation therapy < or =1 year in patients with idiopathic VTE is no

…
Developmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review.
Bikdeli B, Sadeghipour P, Lou J, Bejjani A, Khairani CD, Rashedi S, Lookstein R, Lansky A, Vedantham S, Sobieszczyk P, Mena-Hurtado C, Aghayev A, Henke P, Mehdipoor G, Tufano A, Chatterjee S, Middeldorp S, Wasan S, Bashir R, Lang IM, Shishehbor MH, Gerhard-Herman M, Giri J, Menard MT, Parikh SA, Mazzolai L, Moores L, Monreal M, Jimenez D, Goldhaber SZ, Krumholz HM, Piazza G. Bikdeli B, et al. Among authors: goldhaber sz. Semin Thromb Hemost. 2024 Jan 4. doi: 10.1055/s-0043-1777991. Online ahead of print. Semin Thromb Hemost. 2024. PMID: 38176425
Surgical techniques for vena cava interruption (ligation, clipping, and plication) to prevent PE have been largely abandoned due to short-term procedural risks and long-term complications, although survivors of prior procedures are occasionally encountered. ...
Surgical techniques for vena cava interruption (ligation, clipping, and plication) to prevent PE have been largely abandoned due to short- …
Cancer and venous thromboembolism.
Piccioli A, Prandoni P, Ewenstein BM, Goldhaber SZ. Piccioli A, et al. Among authors: goldhaber sz. Am Heart J. 1996 Oct;132(4):850-5. doi: 10.1016/s0002-8703(96)90321-x. Am Heart J. 1996. PMID: 8831376 Review.
Currently, primary prevention of venous thrombosis should be considered for cancer patients (1) during and immediately after chemotherapy, (2) when long-term indwelling central venous catheters are placed; or (3) when hospitalization for cancer is characterized by prolonge …
Currently, primary prevention of venous thrombosis should be considered for cancer patients (1) during and immediately after chemotherapy, ( …
Anticoagulation in dilated cardiomyopathy.
Koniaris LS, Goldhaber SZ. Koniaris LS, et al. Among authors: goldhaber sz. J Am Coll Cardiol. 1998 Mar 15;31(4):745-8. doi: 10.1016/s0735-1097(98)00003-5. J Am Coll Cardiol. 1998. PMID: 9525541 Free article. Review.
However, reports of the incidence of thromboembolic events in this population vary widely. There has never been a controlled study of long-term anticoagulation among patients with congestive heart failure due to dilated cardiomyopathy. ...Although many investigators have c …
However, reports of the incidence of thromboembolic events in this population vary widely. There has never been a controlled study of long- …
NOACs for treatment of venous thromboembolism in clinical practice.
Schulman S, Singer D, Ageno W, Casella IB, Desch M, Goldhaber SZ. Schulman S, et al. Among authors: goldhaber sz. Thromb Haemost. 2017 Jun 28;117(7):1317-1325. doi: 10.1160/TH17-01-0065. Epub 2017 Apr 20. Thromb Haemost. 2017. PMID: 28424821 Review.
Patient satisfaction, quality of life, and adherence and persistence in clinical practice with the drug regimen can only be assessed with an open-label design. Evaluation of risk for long-term sequelae of the disease requires much longer follow-up than is possible in regis …
Patient satisfaction, quality of life, and adherence and persistence in clinical practice with the drug regimen can only be assessed with an …
60 results